Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations

NCT02052778 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT02052778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 21, 2014
Completion date
October 22, 2024
Enrollment
407 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and metastatic cancer patients with tumors harboring fgf/fgfr tumors, breast cancer, cholangiocarcinoma, gastric cancer, primary cns tumors, urothelial cancer